LaminarForge

Research context

Useful research tooling starts with reproducible test units.

LaminarForge is exploring modular lab automation to support progress toward an HSV-2 cure. These notes cover liquid handling, vessel interfaces, and possible future research applications. Designs and scientific fit remain under evaluation.

Why this exists

Start with the workflow before making a performance claim.

TEST
Define the sample and targetA useful assay starts with a specific sample type, molecular target, preparation method, control strategy, and intended result.
DATA
Validate before interpretingTemperature stability, contamination controls, positive and negative controls, timing, and repeatability come before a clinical claim.
AAV delivery

The delivery shell matters before any payload claim matters.

Known fieldOrgan-on-chip is realReusable cassettes, perfused plates, modular fluidics, and AAV-on-chip studies already exist. LaminarForge is not claiming to invent the category.
Under investigationWhere could better integration help?We are comparing existing equipment and software against specific workflow needs, including integration effort, recurring costs, reproducibility, and access to design information.
LaminarForge aimMake useful workflows repeatableThe current direction is modular liquid handling across multiple vessels, reusing existing designs where they fit. Vessel format, interfaces, and capacity remain open.
Earlier 16-slot concept

Cassette and vessel interfaces remain open.

This illustration records an earlier 4 by 4 carrier idea. It is one concept to compare with existing vessels and carriers, rather than a selected system architecture.

The current priority is liquid handling across multiple vessels. Capacity, compatibility, cost, and reliability will need evidence before a format is chosen.

Slot 1Slot 2Slot 3Slot 4Slot 5Slot 6Slot 7Slot 8Slot 9Slot 10Slot 11Slot 12Slot 13Slot 14Slot 15Slot 16
Validation first

Cells are not software containers.

01Define the measurable questionEach test begins with a specific sample, target, workflow, and acceptance criterion so the result can be interpreted without overclaiming.
02Track delivery selectivityAAV capsids are delivery shells. If future therapies need to reach specific cell types, capsid behavior across relevant cell models needs to be measurable.
03Evaluate vessel and module interfacesCompare existing designs against the chosen workflow before selecting vessel format, capacity, and connections.
04Validate before biology claimsNo-cell and media-only checks come first: fit, leaks, bubbles, flow balance, environmental logging, imaging access, and run records.
Source trail

Adjacent work to inspect first.

Multiplex viral tropism assay

AAV serotypes across complex human organoid cell populations with single-cell readouts.

Multi-trait AAV capsid engineering

Large capsid libraries and computational screening for delivery traits.

Reusable MPS cassette

Reusable clamped cassette and replaceable inserts for perfused microphysiological systems.

Fluidic circuit board

Modular operation of microfluidic chips for parallel cell culture and liquid dosing.

Emulate AAV organ-chip example

Commercial organ-chip framing for AAV transduction and toxicity work.

AKITA scalable organ-on-chip platform

Plate-format organ-on-chip platform with standardized layout and TEER readouts.